Targeting hypoxia in cancer therapy
The DOI matches its Crossref record; 190 of the 190 references it cites were found in a registry or an index.
Abstract
Hypoxia is a feature of most tumours, albeit with variable incidence and severity within a given patient population. It is a negative prognostic and predictive factor owing to its multiple contributions to chemoresistance, radioresistance, angiogenesis, vasculogenesis, invasiveness, metastasis, resistance to cell death, altered metabolism and genomic instability. Given its central role in tumour progression and resistance to therapy, tumour hypoxia might well be considered the best validated target that has yet to be exploited in oncology. However, despite an explosion of information on hypoxia, there are still major questions to be addressed if the long-standing goal of exploiting tumour hypoxia is to be realized. Here, we review the two main approaches, namely bioreductive prodrugs and inhibitors of molecular targets upon which hypoxic cell survival depends. We address the particular challenges and opportunities these overlapping strategies present, and discuss the central importance of emerging diagnostic tools for patient stratification in targeting hypoxia.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Several approaches for targeting hypoxic tumor cells have been proposed including hypoxia-activated prodrugs, gene therapy, recombinant anaerobic bacteria, specific targeting of HIFs, or targeting pathways important in hypoxic cells such as the mTOR and UPR pathways (Melillo, 2007;Wilson & Hay, 2011;Semenza, 2012).”
From Therapeutic targeting of hypoxia and hypoxia-inducible factors in cancer (2016) · cites this paper as Wilson & Hay, 2011
In the citing paper
“Endothelial cells, fibroblasts, and immune cells are the three main cell types which appear in most cancers and are vital components in enhancing the drug resistance of tumors [103, 114-120].”
From Microfluidic modelling of the tumor microenvironment for anti-cancer drug development (2019) · cites this paper as [120]
In the citing paper
“Endothelial cells, fibroblasts, and immune cells are the three main cell types which appear in most cancers and are vital components in enhancing the drug resistance of tumors [103, 114-120].”
From Microfluidic modelling of the tumor microenvironment for anti-cancer drug development (2019) · cites this paper as [120]
In the citing paper
“Hypoxic environment, on the other hand, is known to reduce cytotoxicity of many anticancer drugs, affect angiogenesis, promote metastasis and alter the metabolic activity of cancer cells [183,197].”
From Microfluidic modelling of the tumor microenvironment for anti-cancer drug development (2019) · cites this paper as [183]
In the citing paper
“In addition to increasing drug resistance, a high SS could influence tumor cells' gene expression, comprise immune cells ability to kill cancerous cells or even turn macrophages to tumorfriendly cells, thereby enhancing the metastatic potential of cancer cells [180-184].”
From Microfluidic modelling of the tumor microenvironment for anti-cancer drug development (2019) · cites this paper as [183]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Targeting HIF-1 for cancer therapy
Semenza, G. L. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1187 · Cited by 6,717 · cited 1×
“The two main oxygen-responsive signalling pathways that mediate adaptation to hypoxia are centred on the HIF family of transcription factor”
BackgroundNormalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy
Jain, R. K. (2005) · Science · doi:10.1126/science.1104819 · Cited by 5,527 · cited 1×
“Initially, hypoxia arises because of oxygen diffusion limitations in avascular primary tumours or their metastases, but the tumour microvasculature (induced in part as a response to this hypoxia) is highly abnorma”
BackgroundNetwork medicine: a network-based approach to human disease
Barabási, A.-L., Gulbahce, N., & Loscalzo, J. (2011) · Nature Reviews Genetics · doi:10.1038/nrg2918 · Cited by 5,034
Regulation of cancer cell metabolism
Cairns, R. A., Harris, I. S., & Mak, T. W. (2011) · Nature Reviews Cancer · doi:10.1038/nrc2981 · Cited by 4,744
Drug penetration in solid tumours
Minchinton, A. I., & Tannock, I. F. (2006) · Nature reviews. Cancer · doi:10.1038/nrc1893 · Cited by 2,805
Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours
Graeber, T. G., Osmanian, C., Jacks, T., Housman, D. E., Koch, C. J., Lowe, S. W., & Giaccia, A. J. (1996) · Nature · doi:10.1038/379088a0 · Cited by 2,300
DNA repair pathways as targets for cancer therapy
Helleday, T., Petermann, E., Lundin, C., Hodgson, B., & Sharma, R. A. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2342 · Cited by 1,666
Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice
Sonveaux, P., Végran, F., Schroeder, T., Wergin, M. C., Verrax, J., Rabbani, Z. N., De Saedeleer, C. J., Kennedy, K. M., Diepart, C., Jordan, B. F., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci36843 · Cited by 1,624
Mitochondrial complex III is required for hypoxia-induced ROS production and cellular oxygen sensing
Guzy, R. D., Hoyos, B., Robin, E., Chen, H., Liu, L., Mansfield, K. D., Simon, M. C., Hammerling, U., & Schumacker, P. T. (2005) · Cell Metabolism · doi:10.1016/j.cmet.2005.05.001 · Cited by 1,545
Brugarolas, J., Lei, K., Hurley, R. L., Manning, B. D., Reiling, J. H., Hafen, E., Witters, L. A., Ellisen, L. W., & Kaelin, W. G. (2004) · Genes & Development · doi:10.1101/gad.1256804 · Cited by 1,384 · cited 1×
“The mechanisms include activation of the tuberous sclerosis 1 (TSC1)–TSC2 complex through the HIF1 target gene DNA-damage-inducible transcript 4 ( DDIT4 ; also known as REDD1”
Background
Cited by
Items 201–300 of 1,015
McDonald, P. C., Chafe, S. C., Brown, W. S., Saberi, S., Swayampakula, M., Venkateswaran, G., Nemirovsky, O., Gillespie, J. A., Karasinska, J. M., Kalloger, S. E., et al. (2019) · Gastroenterology · doi:10.1053/j.gastro.2019.05.004 · Cited by 221
Li, Z., Li, X., Gao, X., Zhang, Y., Shi, W., & Ma, H. (2013) · Analytical Chemistry · doi:10.1021/ac400750r · Cited by 225
Genomic Analyses Reveal Potential Independent Adaptation to High Altitude in Tibetan Chickens
Wang, M.-S., Li, Y., Peng, M.-S., Zhong, L., Wang, Z.-J., Li, Q.-Y., Tu, X.-L., Dong, Y., Zhu, C.-L., Wang, L., et al. (2015) · Molecular Biology and Evolution · doi:10.1093/molbev/msv071 · Cited by 224
Tumor hypoxia as a driving force in genetic instability
Luoto, K. R., Kumareswaran, R., & Bristow, R. G. (2013) · Genome Integrity · doi:10.1186/2041-9414-4-5 · Cited by 223
Li, N., Li, Y., Han, Y., Pan, W., Zhang, T., & Tang, B. (2014) · Analytical Chemistry · doi:10.1021/ac5000587 · Cited by 222
Regulation of Tumor Progression by Programmed Necrosis
Lee, S. Y., Ju, M. K., Jeon, H. M., Jeong, E. K., Lee, Y. J., Kim, C. H., Park, H. G., Han, S. I., & Kang, H. S. (2018) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2018/3537471 · Cited by 215
Glioma stem cells and their roles within the hypoxic tumor microenvironment
Boyd, N. H., Tran, A. N., Bernstock, J. D., Etminan, T., Jones, A. B., Gillespie, G. Y., Friedman, G. K., & Hjelmeland, A. B. (2021) · Theranostics · doi:10.7150/thno.41692 · Cited by 221
Biomimetic Liposomal Nanoplatinum for Targeted Cancer Chemophototherapy
Liu, X., Dong, X., Yang, S., Lai, X., Liu, H., Gao, Y., Feng, H., Zhu, M., Yuan, Y., Lu, Q., et al. (2021) · Advanced Science · doi:10.1002/advs.202003679 · Cited by 220
The Meaning, Measurement and Modification of Hypoxia in the Laboratory and the Clinic
Hammond, E. M., Asselin, M.-C., Forster, D., O'Connor, J. P. B., Senra, J. M., & Williams, K. J. (2014) · Clinical Oncology · doi:10.1016/j.clon.2014.02.002 · Cited by 217
Tumor hypoxia: From basic knowledge to therapeutic implications
Liao, C., Liu, X., Zhang, C., & Zhang, Q. (2023) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.12.011 · Cited by 223
Molecular mechanisms mediating metastasis of hypoxic breast cancer cells
Semenza, G. L. (2012) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2012.08.001 · Cited by 217
Zhou, X., You, M., Wang, F., Wang, Z., Gao, X., Jing, C., Liu, J., Guo, M., Li, J., Luo, A., et al. (2021) · Advanced Materials · doi:10.1002/adma.202100556 · Cited by 214
Use of macrophages to deliver therapeutic and imaging contrast agents to tumors
Choi, J., Kim, H.-Y., Ju, E. J., Jung, J., Park, J., Chung, H.-K., Lee, J. S., Lee, J. S., Park, H. J., Song, S. Y., et al. (2012) · Biomaterials · doi:10.1016/j.biomaterials.2012.02.022 · Cited by 215
Tumor Microenvironment‐Enabled Nanotherapy
Wang, L., Huo, M., Chen, Y., & Shi, J. (2018) · Advanced Healthcare Materials · doi:10.1002/adhm.201701156 · Cited by 213
Cold-inducible proteins CIRP and RBM3, a unique couple with activities far beyond the cold
Zhu, X., Bührer, C., & Wellmann, S. (2016) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-016-2253-7 · Cited by 213
Noman, M. Z., Hasmim, M., Lequeux, A., Xiao, M., Duhem, C., Chouaib, S., Berchem, G., & Janji, B. (2019) · Cells · doi:10.3390/cells8091083 · Cited by 212
Fang, H., Chen, Y., Jiang, Z., He, W., & Guo, Z. (2023) · Accounts of Chemical Research · doi:10.1021/acs.accounts.2c00643 · Cited by 208
Yang, S., Tang, Z., Hu, C., Zhang, D., Shen, N., Yu, H., & Chen, X. (2019) · Advanced Materials · doi:10.1002/adma.201805955 · Cited by 210
Regulation of PD-L1: Emerging Routes for Targeting Tumor Immune Evasion
Wang, Y., Wang, H., Yao, H., Li, C., Fang, J.-Y., & Xu, J. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00536 · Cited by 209
The role of hypoxia-inducible factors in tumor angiogenesis and cell metabolism
Lv, X., Li, J., Zhang, C., Hu, T., Li, S., He, S., Yan, H., Tan, Y., Lei, M., Wen, M., et al. (2017) · Genes & Diseases · doi:10.1016/j.gendis.2016.11.003 · Cited by 209
Metabolic Barriers to T Cell Function in Tumors
Sugiura, A., & Rathmell, J. C. (2018) · The Journal of Immunology · doi:10.4049/jimmunol.1701041 · Cited by 208
“Hypoxia and upregulation of HIF1a in tumors are both associated with poor clinical outcomes in cancer patients (69).”
BackgroundMetabolic Signature Identifies Novel Targets for Drug Resistance in Multiple Myeloma
Maiso, P., Huynh, D., Moschetta, M., Sacco, A., Aljawai, Y., Mishima, Y., Asara, J. M., Roccaro, A. M., Kimmelman, A. C., & Ghobrial, I. M. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-3400 · Cited by 208
Hypoxia as a barrier to immunotherapy in pancreatic adenocarcinoma
Daniel, S. K., Sullivan, K. M., Labadie, K. P., & Pillarisetty, V. G. (2019) · Clinical and Translational Medicine · doi:10.1186/s40169-019-0226-9 · Cited by 207
Autophagy in cancer development, immune evasion, and drug resistance
Niu, X., You, Q., Hou, K., Tian, Y., Wei, P., Zhu, Y., Gao, B., Ashrafizadeh, M., Aref, A. R., Kalbasi, A., et al. (2025) · Drug Resistance Updates · doi:10.1016/j.drup.2024.101170 · Cited by 191
Dual-Phosphorescent Iridium(III) Complexes Extending Oxygen Sensing from Hypoxia to Hyperoxia
Zhang, K. Y., Gao, P., Sun, G., Zhang, T., Li, X., Liu, S., Zhao, Q., Lo, K. K.-W., & Huang, W. (2018) · Journal of the American Chemical Society · doi:10.1021/jacs.8b02492 · Cited by 205
Small‐Molecule Prodrug Nanoassemblies: An Emerging Nanoplatform for Anticancer Drug Delivery
Li, G., Sun, B., Li, Y., Luo, C., He, Z., & Sun, J. (2021) · Small · doi:10.1002/smll.202101460 · Cited by 205
Role of TGFβ in regulation of the tumor microenvironment and drug delivery (Review)
PAPAGEORGIS, P., & STYLIANOPOULOS, T. (2015) · International Journal of Oncology · doi:10.3892/ijo.2015.2816 · Cited by 206
Recent Advances in Nanostrategies Capable of Overcoming Biological Barriers for Tumor Management
Huo, D., Jiang, X., & Hu, Y. (2020) · Advanced Materials · doi:10.1002/adma.201904337 · Cited by 205
Molecular and Cellular Pharmacology of the Hypoxia-Activated Prodrug TH-302
Meng, F., Evans, J. W., Bhupathi, D., Banica, M., Lan, L., Lorente, G., Duan, J.-X., Cai, X., Mowday, A. M., Guise, C. P., et al. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0634 · Cited by 203
Panarese, I., Aquino, G., Ronchi, A., Longo, F., Montella, M., Cozzolino, I., Roccuzzo, G., Colella, G., Caraglia, M., & Franco, R. (2019) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2019.1561288 · Cited by 204
He, Z., & Zhang, S. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.741305 · Cited by 203
Sedlakova, O. (2014) · Frontiers in Physiology · doi:10.3389/fphys.2013.00400 · Cited by 202
Cobalt derivatives as promising therapeutic agents
Heffern, M. C., Yamamoto, N., Holbrook, R. J., Eckermann, A. L., & Meade, T. J. (2013) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2012.11.019 · Cited by 204
Carbonic anhydrase inhibitors as antitumor/antimetastatic agents: a patent review (2008–2018)
Nocentini, A., & Supuran, C. T. (2018) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2018.1508453 · Cited by 197
Chen, G., Cao, Y., Tang, Y., Yang, X., Liu, Y., Huang, D., Zhang, Y., Li, C., & Wang, Q. (2020) · Advanced Science · doi:10.1002/advs.201903783 · Cited by 201
Hypoxic tumor microenvironment: Opportunities to develop targeted therapies
Patel, A., & Sant, S. (2016) · Biotechnology Advances · doi:10.1016/j.biotechadv.2016.04.005 · Cited by 201
Exosomes in the hypoxic TME: from release, uptake and biofunctions to clinical applications
He, G., Peng, X., Wei, S., Yang, S., Li, X., Huang, M., Tang, S., Jin, H., Liu, J., Zhang, S., et al. (2022) · Molecular Cancer · doi:10.1186/s12943-021-01440-5 · Cited by 201
Gao, S., Yang, D., Fang, Y., Lin, X., Jin, X., Wang, Q., Wang, X., Ke, L., & Shi, K. (2019) · Theranostics · doi:10.7150/thno.29431 · Cited by 199
Liu, Y., Ji, X., Tong, W. W. L., Askhatova, D., Yang, T., Cheng, H., Wang, Y., & Shi, J. (2018) · Angewandte Chemie International Edition · doi:10.1002/anie.201710144 · Cited by 199
Metabolism in tumor microenvironment: Implications for cancer immunotherapy
Shi, R., Tang, Y., & Miao, H. (2020) · MedComm · doi:10.1002/mco2.6 · Cited by 198
Oudin, M. J., & Weaver, V. M. (2016) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2016.81.030817 · Cited by 196
Borad, M. J., Reddy, S. G., Bahary, N., Uronis, H. E., Sigal, D., Cohn, A. L., Schelman, W. R., Stephenson, J., Chiorean, E. G., Rosen, P. J., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.55.7504 · Cited by 197
“Novel therapeutics that specifically target the resistant hypoxic zones may provide additional antitumor activity and clinical benefit when combined with conventional treatments.(10,11) TH-302 (Threshold Pharmaceuticals, South San Francisco, CA, and Merck KGaA, Darmstadt, Germany) is a hypoxia-activated, cytotoxic pro…”
Yang, H., Zhang, H., Yang, Y., Wang, X., Deng, T., Liu, R., Ning, T., Bai, M., Li, H., Zhu, K., et al. (2020) · Theranostics · doi:10.7150/thno.44419 · Cited by 196
Corre, I., Paris, F., & Huot, J. (2017) · Oncotarget · doi:10.18632/oncotarget.18264 · Cited by 194
Enhanced Anticancer Efficacy by ATP‐Mediated Liposomal Drug Delivery
Mo, R., Jiang, T., & Gu, Z. (2014) · Angewandte Chemie International Edition · doi:10.1002/anie.201400268 · Cited by 194
Review of Functionalized Nanomaterials for Photothermal Therapy of Cancers
Bian, W., Wang, Y., Pan, Z., Chen, N., Li, X., Wong, W.-L., Liu, X., He, Y., Zhang, K., & Lu, Y.-J. (2021) · ACS Applied Nano Materials · doi:10.1021/acsanm.1c01903 · Cited by 194
Lee, L. C.-C., Leung, K.-K., & Lo, K. K.-W. (2017) · Dalton Transactions · doi:10.1039/c7dt03465b · Cited by 193
Panagi, M., Voutouri, C., Mpekris, F., Papageorgis, P., Martin, M. R., Martin, J. D., Demetriou, P., Pierides, C., Polydorou, C., Stylianou, A., et al. (2020) · Theranostics · doi:10.7150/thno.36936 · Cited by 191
Development of Inhibitors Targeting Hypoxia-Inducible Factor 1 and 2 for Cancer Therapy
Yu, T., Tang, B., & Sun, X. (2017) · Yonsei Medical Journal · doi:10.3349/ymj.2017.58.3.489 · Cited by 191
New-generation advanced PROTACs as potential therapeutic agents in cancer therapy
Wang, C., Zhang, Y., Chen, W., Wu, Y., & Xing, D. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02024-9 · Cited by 188
A mechanistic investigation of the oxygen fixation hypothesis and oxygen enhancement ratio
Robert Grimes, D., & Partridge, M. (2015) · Biomedical Physics & Engineering Express · doi:10.1088/2057-1976/1/4/045209 · Cited by 188
Cui, H., Seubert, B., Stahl, E., Dietz, H., Reuning, U., Moreno-Leon, L., Ilie, M., Hofman, P., Nagase, H., Mari, B., et al. (2015) · Oncogene · doi:10.1038/onc.2014.300 · Cited by 190
Sun, J. D., Liu, Q., Wang, J., Ahluwalia, D., Ferraro, D., Wang, Y., Duan, J.-X., Ammons, W. S., Curd, J. G., Matteucci, M. D., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1980 · Cited by 190
The Clinical Significance of Hypoxia in Human Cancers
Dhani, N., Fyles, A., Hedley, D., & Milosevic, M. (2015) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2014.11.002 · Cited by 188
Hypoxia-Inducible miR-210 Regulates the Susceptibility of Tumor Cells to Lysis by Cytotoxic T Cells
Noman, M. Z., Buart, S., Romero, P., Ketari, S., Janji, B., Mari, B., Mami-Chouaib, F., & Chouaib, S. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-1383 · Cited by 188
Guo, X., Liu, F., Deng, J., Dai, P., Qin, Y., Li, Z., Wang, B., Fan, A., Wang, Z., & Zhao, Y. (2020) · ACS Nano · doi:10.1021/acsnano.0c00764 · Cited by 187
Interfering with Tumor Hypoxia for Radiotherapy Optimization
Telarovic, I., Wenger, R. H., & Pruschy, M. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-02000-x · Cited by 185
Multifunctional MnO2 nanoparticles for tumor microenvironment modulation and cancer therapy
Yang, G., Ji, J., & Liu, Z. (2021) · WIREs Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1720 · Cited by 185
Kucharzewska, P., & Belting, M. (2013) · Journal of Extracellular Vesicles · doi:10.3402/jev.v2i0.20304 · Cited by 186
Hypoxic Induction of Vasorin Regulates Notch1 Turnover to Maintain Glioma Stem-like Cells
Man, J., Yu, X., Huang, H., Zhou, W., Xiang, C., Huang, H., Miele, L., Liu, Z., Bebek, G., Bao, S., et al. (2018) · Cell Stem Cell · doi:10.1016/j.stem.2017.10.005 · Cited by 186
The critical role of AMPK in driving Akt activation under stress, tumorigenesis and drug resistance
Han, F., Li, C.-F., Cai, Z., Zhang, X., Jin, G., Zhang, W.-N., Xu, C., Wang, C.-Y., Morrow, J., Zhang, S., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-07188-9 · Cited by 183
Applications and challenges of ultra-small particle size nanoparticles in tumor therapy
Xu, J., Song, M., Fang, Z., Zheng, L., Huang, X., & Liu, K. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.12.028 · Cited by 185
Jo, Y., Choi, N., Kim, K., Koo, H.-J., Choi, J., & Kim, H. N. (2018) · Theranostics · doi:10.7150/thno.29098 · Cited by 183
Oxygen‐Sensing Methods in Biomedicine from the Macroscale to the Microscale
Roussakis, E., Li, Z., Nichols, A. J., & Evans, C. L. (2015) · Angewandte Chemie International Edition · doi:10.1002/anie.201410646 · Cited by 184
Nanoplatform-based cascade engineering for cancer therapy
Chen, J., Zhu, Y., Wu, C., & Shi, J. (2020) · Chemical Society Reviews · doi:10.1039/d0cs00607f · Cited by 182
Breaking the Depth Dependence by Nanotechnology‐Enhanced X‐Ray‐Excited Deep Cancer Theranostics
Fan, W., Tang, W., Lau, J., Shen, Z., Xie, J., Shi, J., & Chen, X. (2019) · Advanced Materials · doi:10.1002/adma.201806381 · Cited by 182
Hypoxia Promotes Tumor Growth in Linking Angiogenesis to Immune Escape
Chouaib, S., Messai, Y., Couve, S., Escudier, B., Hasmim, M., & Noman, M. Z. (2012) · Frontiers in Immunology · doi:10.3389/fimmu.2012.00021 · Cited by 180
Yue, X., Lan, F., & Xia, T. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.07.011 · Cited by 180
Role of the VEGF/VEGFR Axis in Cancer Biology and Therapy
(2012) · Advances in Cancer Research · doi:10.1016/b978-0-12-386503-8.00006-5 · Cited by 180
Bao, B., Azmi, A. S., Ali, S., Ahmad, A., Li, Y., Banerjee, S., Kong, D., & Sarkar, F. H. (2012) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2012.04.008 · Cited by 180
Nanomaterials to relieve tumor hypoxia for enhanced photodynamic therapy
Zhang, C., Qin, W.-J., Bai, X.-F., & Zhang, X.-Z. (2020) · Nano Today · doi:10.1016/j.nantod.2020.100960 · Cited by 180
Dreaden, E. C., Morton, S. W., Shopsowitz, K. E., Choi, J.-H., Deng, Z. J., Cho, N.-J., & Hammond, P. T. (2014) · ACS Nano · doi:10.1021/nn502861t · Cited by 179
Maftouh, M., Avan, A., Sciarrillo, R., Granchi, C., Leon, L. G., Rani, R., Funel, N., Smid, K., Honeywell, R., Boggi, U., et al. (2014) · British Journal of Cancer · doi:10.1038/bjc.2013.681 · Cited by 180
Emerging targeted agents in metastatic breast cancer
Zardavas, D., Baselga, J., & Piccart, M. (2013) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.29 · Cited by 178
Biosurfactants Produced by Marine Microorganisms with Therapeutic Applications
Gudiña, E., Teixeira, J., & Rodrigues, L. (2016) · Marine Drugs · doi:10.3390/md14020038 · Cited by 179
Nanoformulations for combination or cascade anticancer therapy
Miao, L., Guo, S., Lin, C. M., Liu, Q., & Huang, L. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.06.003 · Cited by 178
Lessons from patient-derived xenografts for better in vitro modeling of human cancer
Choi, S. Y. C., Lin, D., Gout, P. W., Collins, C. C., Xu, Y., & Wang, Y. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2014.09.009 · Cited by 177
New PARP targets for cancer therapy
Vyas, S., & Chang, P. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3748 · Cited by 176
Oncometabolites: Unconventional triggers of oncogenic signalling cascades
Sciacovelli, M., & Frezza, C. (2016) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2016.04.025 · Cited by 178
Progress of exosomes in the diagnosis and treatment of lung cancer
Xu, K., Zhang, C., Du, T., Gabriel, A. N. A., Wang, X., Li, X., Sun, L., Wang, N., Jiang, X., & Zhang, Y. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.111111 · Cited by 177
Overcoming disappointing results with antiangiogenic therapy by targeting hypoxia
Rapisarda, A., & Melillo, G. (2012) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2012.64 · Cited by 176
Transition metal complexes as photosensitizers for integrated cancer theranostic applications
Li, J., & Chen, T. (2020) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2020.213355 · Cited by 176
Hypoxia, endoplasmic reticulum stress and chemoresistance: dangerous liaisons
Akman, M., Belisario, D. C., Salaroglio, I. C., Kopecka, J., Donadelli, M., De Smaele, E., & Riganti, C. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-020-01824-3 · Cited by 174
Reengineering the Tumor Microenvironment to Alleviate Hypoxia and Overcome Cancer Heterogeneity
Martin, J. D., Fukumura, D., Duda, D. G., Boucher, Y., & Jain, R. K. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a027094 · Cited by 175
Vincenz, L., Jäger, R., O'Dwyer, M., & Samali, A. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0782 · Cited by 175
“disulphide bond formation, hypoxia leads to an increase in misfolded proteins triggering IRE1a activation and XBP1 splicing (25).”
BackgroundKinugasa, Y., Matsui, T., & Takakura, N. (2014) · Stem Cells · doi:10.1002/stem.1556 · Cited by 175
Enzyme production of d-gluconic acid and glucose oxidase: successful tales of cascade reactions
Kornecki, J. F., Carballares, D., Tardioli, P. W., Rodrigues, R. C., Berenguer-Murcia, Á., Alcántara, A. R., & Fernandez-Lafuente, R. (2020) · Catalysis Science & Technology · doi:10.1039/d0cy00819b · Cited by 174
Conditionally Activatable Photoredox Catalysis in Living Systems
Li, M., Gebremedhin, K. H., Ma, D., Pu, Z., Xiong, T., Xu, Y., Kim, J. S., & Peng, X. (2022) · Journal of the American Chemical Society · doi:10.1021/jacs.1c07372 · Cited by 173
Thambi, T., Park, J. H., & Lee, D. S. (2016) · Chemical Communications · doi:10.1039/c6cc02972h · Cited by 171
Molecular targeting of hypoxia in radiotherapy
Rey, S., Schito, L., Koritzinsky, M., & Wouters, B. G. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.10.002 · Cited by 172
Yang, B., Chen, Y., & Shi, J. (2019) · Materials Science and Engineering: R: Reports · doi:10.1016/j.mser.2019.01.001 · Cited by 171
Cancer Metabolism and Drug Resistance
Rahman, M., & Hasan, M. (2015) · Metabolites · doi:10.3390/metabo5040571 · Cited by 170
Imaging tumour hypoxia with oxygen-enhanced MRI and BOLD MRI
O'Connor, J. P. B., Robinson, S. P., & Waterton, J. C. (2019) · The British Journal of Radiology · doi:10.1259/bjr.20180642 · Cited by 169
Modulation of the tumor vasculature and oxygenation to improve therapy
Siemann, D. W., & Horsman, M. R. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2015.06.006 · Cited by 169
“The fact that very low levels of oxygen are unique to solid tumors provides an excellent basis for tumor selectivity which continues to drive the preclinical development and clinical evaluation of this therapeutic approach (Table 1; Wilson & Hay, 2011).”
Okuda, K., Okabe, Y., Kadonosono, T., Ueno, T., Youssif, B. G. M., Kizaka-Kondoh, S., & Nagasawa, H. (2012) · Bioconjugate Chemistry · doi:10.1021/bc2004704 · Cited by 169
Leveraging Physiology for Precision Drug Delivery
Sun, W., Hu, Q., Ji, W., Wright, G., & Gu, Z. (2017) · Physiological Reviews · doi:10.1152/physrev.00015.2016 · Cited by 169
Kill-painting of hypoxic tumours in charged particle therapy
Tinganelli, W., Durante, M., Hirayama, R., Krämer, M., Maier, A., Kraft-Weyrather, W., Furusawa, Y., Friedrich, T., & Scifoni, E. (2015) · Scientific Reports · doi:10.1038/srep17016 · Cited by 167
CircBCAR3 accelerates esophageal cancer tumorigenesis and metastasis via sponging miR-27a-3p
Xi, Y., Shen, Y., Wu, D., Zhang, J., Lin, C., Wang, L., Yu, C., Yu, B., & Shen, W. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01615-8 · Cited by 163
Radiosensitization by gold nanoparticles: Will they ever make it to the clinic?
Cui, L., Her, S., Borst, G. R., Bristow, R. G., Jaffray, D. A., & Allen, C. (2017) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2017.07.007 · Cited by 164
Impact of cancer metabolism on therapy resistance – Clinical implications
Gonçalves, A. C., Richiardone, E., Jorge, J., Polónia, B., Xavier, C. P. R., Salaroglio, I. C., Riganti, C., Vasconcelos, M. H., Corbet, C., & Sarmento-Ribeiro, A. B. (2021) · Drug Resistance Updates · doi:10.1016/j.drup.2021.100797 · Cited by 164
Metadata
- Authors
- Wilson, W. R., & Hay, M. P.
- Affiliations
- University of Auckland (NZ)
- Corresponding author
- Wilson, William R.
- Venue
- Nature Reviews Cancer
- Published
- 2011-05-24
- Volume
- 11
- Issue
- 6
- Pages
- 393-410
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W2024903578
- Cited by
- 3,172
- References
- 190
- Citations by year
- 2026: 109 · 2025: 165 · 2024: 196 · 2023: 206 · 2022: 268 · 2021: 298 · 2020: 319 · 2019: 238 · 2018: 274 · 2017: 238 · 2016: 223 · 2015: 188 · 2014: 164 · 2013: 156 · 2012: 102
- FWCI
- 10.38
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature reviews. Cancer (publishedVersion)
- PubMed (publishedVersion)
- ResearchSpace (University of Auckland) (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Physical Sciences › Chemistry › Organic Chemistry › Heterocyclic Compound Synthesis and Bioactivity
- Keywords
- tumor hypoxia, cancer therapy, bioreductive prodrugs, chemoresistance, radioresistance (biology), angiogenesis, metastasis, cancer metabolism, genomic instability, patient stratification
- MeSH terms
- Antineoplastic Agents, Humans, Neoplasms, Prodrugs, Prognosis, Biomarkers, Tumor, Cell Hypoxia, Reactive Oxygen Species, Molecular Targeted Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.